Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Trial Profile

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Everolimus (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Gastrointestinal cancer; Liver metastases; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms EVACEL
  • Most Recent Events

    • 12 Jun 2018 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
    • 12 Jun 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2018.
    • 02 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top